Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer
Hart, C. A.
Shanks, Jonathan H
Clarke, Noel W
AffiliationGenito Urinary Cancer Research Group, Division of Cancer Sciences, Faculty of Biology, Medicine & Health, The University of Manchester and FASTMAN, Prostate Cancer UK & Movember Centre of Excellence, Manchester, UK
MetadataShow full item record
AbstractBackground: The key process of mesenchymal to amoeboid transition (MAT), which enables prostate cancer (PCa) transendothelial migration and subsequent development of metastases in red bone marrow stroma, is driven by phosphorylation of EphA2S897 by pAkt, which is induced by the omega-6 polyunsaturated fatty acid arachidonic acid. Here we investigate the influence of EphA2 signalling in PCa progression and long-term survival. Methods: The mechanisms underpinning metastatic biopotential of altered EphA2 signalling in relation to PTEN status were assessed in vitro using canonical (EphA2D739N) and non-canonical (EphA2S897G) PC3-M mutants, interrogation of publicly available PTEN-stratified databases and clinical validation using a PCa TMA (n = 177) with long-term follow-up data. Spatial heterogeneity of EphA2 was assessed using a radical prostatectomy cohort (n = 67). Results: Non-canonical EphA2 signalling via pEphA2S897 is required for PCa transendothelial invasion of bone marrow endothelium. High expression of EphA2 or pEphA2S897 in a PTENlow background is associated with poor overall survival. Expression of EphA2, pEphA2S897 and the associated MAT marker pMLC2 are spatially regulated with the highest levels found within lesion areas within 500 µm of the prostate margin. Conclusion: EphA2 MAT-related signalling confers transendothelial invasion. This is associated with a substantially worse prognosis in PTEN-deficient PCa.
CitationSachdeva A, Hart CA, Kim K, Tawadros T, Oliveira P, Shanks J, et al. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer. British journal of cancer. 2022 Jul 22. PubMed PMID: 35869144. Epub 2022/07/23. eng.
JournalBritish Journal of Cancer
- Ligand-independent activation of EphA2 by arachidonic acid induces metastasis-like behaviour in prostate cancer cells.
- Authors: Tawadros T, Brown MD, Hart CA, Clarke NW
- Issue date: 2012 Nov 6
- Phosphorylation of EphA2 receptor and vasculogenic mimicry is an indicator of poor prognosis in invasive carcinoma of the breast.
- Authors: Mitra D, Bhattacharyya S, Alam N, Sen S, Mitra S, Mandal S, Vignesh S, Majumder B, Murmu N
- Issue date: 2020 Jan
- Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation.
- Authors: Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB
- Issue date: 2016 Sep 1
- EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
- Authors: Garcia-Monclús S, López-Alemany R, Almacellas-Rabaiget O, Herrero-Martín D, Huertas-Martinez J, Lagares-Tena L, Alba-Pavón P, Hontecillas-Prieto L, Mora J, de Álava E, Rello-Varona S, Giangrande PH, Tirado OM
- Issue date: 2018 Sep 1
- Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2.
- Authors: Kawai H, Kobayashi M, Hiramoto-Yamaki N, Harada K, Negishi M, Katoh H
- Issue date: 2013